Publications by authors named "Peter Ambros"

Claim this Profile
S
Sensitive detection of minimal residual disease and immunotherapy targets by multi-modal bone marrow analysis in high-risk neuroblastoma - a multi-center study.
Nina U Gelineau, Eva Bozsaky, Lieke M J van Zogchel, Fikret Rifatbegovic, Daria Lazic, Peter F Ambros, Inge M Ambros

J Exp Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International neuroblastoma risk group consortium: a model of a networking for rare cancers.
Susan L Cohn, Wendy B London, Gudrun Schleiermacher, Lucas Moreno, Inge M Ambros, Peter F Ambros

J Natl Cancer Inst· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.
Tim Flaadt, Ruth L Ladenstein, Martin Ebinger, Holger N Lode, Helga Björk Arnardóttir, Peter F Ambros

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human repair-related Schwann cells adopt functions of antigen-presenting cells in vitro.
Jakob Berner, Tamara Weiss, Helena Sorger, Fikret Rifatbegovic, Max Kauer, Peter F Ambros, Inge M Ambros

Glia· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma.
Felix Schriegel, Sabine Taschner-Mandl, Marie Bernkopf, Uwe Grunwald, Nikolai Siebert, Peter F Ambros, Inge Ambros

J Cancer Res Clin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup.
Angela Martinez-Monleon, Hanna Kryh Öberg, Jennie Gaarder, Ana P Berbegall, Niloufar Javanmardi, Inge M Ambros, Peter F Ambros

Sci Rep· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions.
Karin Schmelz, Joern Toedling, Matt Huska, Maja C Cwikla, Louisa-Marie Kruetzfeldt, Peter F Ambros, Inge M Ambros

Nat Commun· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency and Prognostic Impact of Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).
Angela Bellini, Ulrike Pötschger, Virginie Bernard, Eve Lapouble, Sylvain Baulande, Peter F Ambros

J Clin Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.
Alberto Garaventa, Ulrike Poetschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Peter Ambros

J Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Landscape of Bone Marrow Metastasis in Human Neuroblastoma Unraveled by Transcriptomics and Deep Multiplex Imaging.
Daria Lazic, Florian Kromp, Fikret Rifatbegovic, Peter Repiscak, Michael Kirr, Inge M Ambros, Peter F Ambros

Cancers (Basel)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Deep Learning Architectures for Complex Immunofluorescence Nuclear Image Segmentation.
Florian Kromp, Lukas Fischer, Eva Bozsaky, Inge M Ambros, Wolfgang Dorr, Peter F Ambros

IEEE Trans Med Imaging· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden.
Peter Peneder, Adrian M Stütz, Didier Surdez, Manuela Krumbholz, Sabine Semper, Inge M Ambros, Peter F Ambros

Nat Commun· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Schwann cell plasticity regulates neuroblastic tumor cell differentiation via epidermal growth factor-like protein 8.
Tamara Weiss, Sabine Taschner-Mandl, Lukas Janker, Andrea Bileck, Fikret Rifatbegovic, Peter F Ambros, Inge M Ambros

Nat Commun· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94.
Stefan Fiedler, Inge M Ambros, Evgenia Glogova, Martin Benesch, Christian Urban, Peter F Ambros

Cancers (Basel)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome.
Sabine A Hartlieb, Lina Sieverling, Michal Nadler-Holly, Matthias Ziehm, Umut H Toprak, Peter Ambros

Nat Commun· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable -Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.
Inge M Ambros, Gian-Paolo Tonini, Ulrike Pötschger, Nicole Gross, Véronique Mosseri, Peter F Ambros

J Clin Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study.
Keith Holmes, Ulrike Pötschger, Andrew D J Pearson, Sabine Sarnacki, Giovanni Cecchetto, Peter F Ambros

J Clin Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Pre-Analytical Sample Handling Conditions for Comprehensive Liquid Biopsy Analysis.
Teresa Gerber, Sabine Taschner-Mandl, Lisa Saloberger-Sindhöringer, Niko Popitsch, Ellen Heitzer, Inge M Ambros, Peter F Ambros

J Mol Diagn· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An annotated fluorescence image dataset for training nuclear segmentation methods.
Florian Kromp, Eva Bozsaky, Fikret Rifatbegovic, Lukas Fischer, Magdalena Ambros, Peter F Ambros, Inge M Ambros

Sci Data· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1).
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Peter Ambros

Cancers (Basel)· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DeepSNP: An End-to-End Deep Neural Network with Attention-Based Localization for Breakpoint Detection in Single-Nucleotide Polymorphism Array Genomic Data.
Hamid Eghbal-Zadeh, Lukas Fischer, Niko Popitsch, Florian Kromp, Sabine Taschner-Mandl, Peter F Ambros, Inge M Ambros

J Comput Biol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detailed Protocols for the Isolation, Culture, Enrichment and Immunostaining of Primary Human Schwann Cells.
Tamara Weiss, Sabine Taschner-Mandl, Peter F Ambros, Inge M Ambros

Methods Mol Biol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Peter Ambros

Lancet Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
Pauline Depuydt, Valentina Boeva, Toby D Hocking, Robrecht Cannoodt, Inge M Ambros, Peter F Ambros

J Natl Cancer Inst· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.
Ana P Berbegall, Dominik Bogen, Ulrike Pötschger, Klaus Beiske, Nick Bown, Peter F Ambros, Inge M Ambros

Br J Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis